Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
← catalyst calendarNCT07609940 · readout in 418 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 4
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
30estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-15 | actual | When the study began enrolling |
| Primary completion | 2027-10-11 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-12-06 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Relapsed/Refractory Multiple Myeloma (RRMM)
Interventions
- Drug: Linvoseltamab — also filed as REGN5458, Lynozyfic™
- Drug: Tocilizumab — also filed as ACTEMRA®
Primary outcomes
what the primary-completion date above is the date OFOccurrence of any grade CRS per American Society for Transplantation and Cellular Therapy (ASTCT) grading
measured Up to 28 days
Severity of any grade CRS per ASTCT grading
measured Up to 28 days
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed